Allopurinol

Excreted Unchanged %
30
Half-Life (Normalesrd) Hours
2-8/Unchanged
Plasma Protein Binding %
<5
Volume Of Distribution L/Kg
0.5
Dose For Normal Renal Function
300 mg q24h
Adjustment For Renal Failure Method
D, I
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
75% [B]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
50% [B]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
25% [B]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: dose, [B]
Supplement For Dialysis [Recommendation Level]: Pd
PD: No data, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50, [D]
References
Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984; 76: 47-56. [PMID: 6691361] / Murrell GA, Rapeport WG. Clinical pharmacokinetics of allopurinol. Clin Phar-macokinet. 1986; 11: 343-53. [PMID: 3536254] / Terkeltaub RA. Clinical practice. Gout. N Engl J Med. 2003; 349: 1647-55. [PMID: 14573737]
Toxicity Notes
Interstitial nephritis. Rare xanthine stones. Renal excretion of active metabolite with T1/2 of 25 hours in patients with normal renal function; T1/2 of one week in patients with ESRD. Exfoliative dermatitis.